IRIS
CANONICA, GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 79.680
NA - Nord America 8.840
AS - Asia 7.083
SA - Sud America 703
Continente sconosciuto - Info sul continente non disponibili 630
AF - Africa 125
OC - Oceania 6
Totale 97.067
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 78.349
US - Stati Uniti d'America 8.045
SG - Singapore 3.085
CN - Cina 1.744
VN - Vietnam 970
FR - Francia 636
BD - Bangladesh 539
BR - Brasile 422
CA - Canada 352
HK - Hong Kong 236
FI - Finlandia 155
DE - Germania 144
GB - Regno Unito 117
AR - Argentina 101
MX - Messico 91
JP - Giappone 79
JM - Giamaica 77
IN - India 66
CO - Colombia 59
CR - Costa Rica 59
IQ - Iraq 58
CH - Svizzera 51
ID - Indonesia 50
NL - Olanda 44
EC - Ecuador 42
HN - Honduras 40
PH - Filippine 35
GT - Guatemala 33
VE - Venezuela 32
TH - Thailandia 29
TT - Trinidad e Tobago 29
MA - Marocco 25
NI - Nicaragua 23
ES - Italia 22
RU - Federazione Russa 21
PK - Pakistan 20
KR - Corea 19
PR - Porto Rico 19
ZA - Sudafrica 19
LT - Lituania 18
SV - El Salvador 18
TR - Turchia 18
IE - Irlanda 17
UZ - Uzbekistan 17
MY - Malesia 15
UA - Ucraina 15
PY - Paraguay 14
JO - Giordania 13
CL - Cile 12
EG - Egitto 12
KE - Kenya 12
NP - Nepal 12
BB - Barbados 11
PL - Polonia 11
AT - Austria 10
DZ - Algeria 10
TW - Taiwan 10
SA - Arabia Saudita 9
SC - Seychelles 9
SE - Svezia 9
DO - Repubblica Dominicana 8
KZ - Kazakistan 8
PA - Panama 8
PE - Perù 8
TN - Tunisia 8
BO - Bolivia 7
BS - Bahamas 6
LB - Libano 6
NG - Nigeria 6
OM - Oman 6
PT - Portogallo 6
AE - Emirati Arabi Uniti 5
AL - Albania 5
AU - Australia 5
AZ - Azerbaigian 5
BA - Bosnia-Erzegovina 5
HR - Croazia 5
IL - Israele 5
SN - Senegal 5
UY - Uruguay 5
BG - Bulgaria 4
GP - Guadalupe 4
HU - Ungheria 4
MD - Moldavia 4
MM - Myanmar 4
RO - Romania 4
SK - Slovacchia (Repubblica Slovacca) 4
AM - Armenia 3
BY - Bielorussia 3
CY - Cipro 3
EE - Estonia 3
GD - Grenada 3
HT - Haiti 3
PS - Palestinian Territory 3
RS - Serbia 3
SY - Repubblica araba siriana 3
XK - ???statistics.table.value.countryCode.XK??? 3
AW - Aruba 2
BE - Belgio 2
BH - Bahrain 2
Totale 96.395
Salva come PNG Salva come JPEG
Città #
Genova 54.592
Genoa 13.010
Rapallo 5.921
Vado Ligure 3.836
San Jose 1.572
Singapore 1.437
Ashburn 1.294
Lauterbourg 613
Council Bluffs 521
New York 258
Ho Chi Minh City 256
Hanoi 242
Hong Kong 218
Santa Clara 207
Beijing 199
Helsinki 151
Los Angeles 127
Milan 127
Frankfurt am Main 111
Phoenix 91
Chicago 89
Rome 89
Dallas 86
Bordighera 84
Tokyo 71
São Paulo 67
Toronto 57
North Bergen 55
Mexico City 52
Naples 51
Kingston 47
Haiphong 46
Zurich 46
Atlanta 45
Buffalo 45
San José 44
Montreal 41
Da Nang 40
Tianjin 38
Philadelphia 31
Brooklyn 29
Houston 29
Amsterdam 28
Bologna 28
Turin 28
Newark 25
Queens 25
Florence 24
Guatemala City 24
Managua 23
Miami 23
Las Vegas 22
Baghdad 21
Bar Harbor 21
San Francisco 21
Biên Hòa 20
Jacksonville 20
Charlotte 19
City of London 19
Guangzhou 19
Shanghai 19
Austin 18
Can Tho 18
Denver 18
Detroit 18
Dublin 18
Hải Dương 17
Orem 17
Palermo 17
San Antonio 17
San Salvador 17
Bogotá 16
Cardiff 16
Guayaquil 16
Orlando 16
Washington 16
Boston 15
Louisville 15
Seattle 15
The Bronx 15
Bangkok 14
Brasília 14
Calgary 14
Jakarta 14
Tashkent 14
Columbus 13
Des Moines 13
London 13
Quito 13
Richmond 13
Belo Horizonte 12
Kansas City 12
San Diego 12
San Pedro Sula 12
Vilnius 12
Bridgetown 11
Dhaka 11
Milwaukee 11
Nuremberg 11
Sacramento 11
Totale 86.959
Salva come PNG Salva come JPEG
Nome #
360 degree perspective on allergic rhinitis management in Italy: A survey of GPs, pharmacists and patients 235
Allergic Rhinitis and its Impact on Asthma (ARIA) Classes in MASK-air Users 227
Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early and late phase reactions after allergen-specific challenge. 223
Personalized medicine in allergy 221
A Review of the Evidence from Comparative Studies of Levocetirizine and Desloratadine for the Symptoms of Allergic Rhinitis 220
Galectin-3: An early predictive biomarker of modulation of airway remodeling in patients with severe asthma treated with omalizumab for 36 months 219
Adhesion molecules in allergy. 218
A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma 218
A three-year double-blind placebo-controlled study with specific oral immunotherapy to Dermatophagoides: evidence of safety and efficacy in paediatric patients. 218
Levocetirizine in persistent allergic rhinitis and asthma: effects on symptoms, quality of life and inflammatory parameters. 216
Administration of a polyvalent mechanical bacterial lysate to elderly patients with COPD: Effects on circulating T, B and NK cells. 215
The perception of Obstructive Sleep Apnoea/Hypopnoea Syndrome (OSAHS) among Italian general practitioners 215
Genuair® Usability Test: Results of a National Public Survey of the Elderly 213
A double-blind, placebo-controlled study on the diagnostic accuracy of an electrodermal test in allergic subjects. 212
Local Side Effects of Sublingual and Oral Immunotherapy 209
Molecular phenotyping and biomarker development: Are we on our way towards targeted therapy for severe asthma? 209
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life 209
Allergen-driven HLA-G expression and secretion in peripheral blood mononuclear cells from allergic rhinitis patients 208
The bacterial lysate Lantigen B reduces the number of acute episodes in patients with recurrent infections of the respiratory tract: the results of a double blind, placebo controlled, multicenter clinical trial 205
A 4-year trial of tiotropium in chronic obstructive pulmonary disease. 204
Anti-IL-5 and IL-5Ra: Efficacy and safety of new therapeutic strategies in severe uncontrolled asthma 204
A new tool to assess and monitor the burden of chronic cough on quality of life: Chronic Cough Impact Questionnaire. 203
60Co therapy as an "allergic breakthrough" in a case of food allergy. 201
ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments 200
Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life 199
Mepolizumab in the management of severe eosinophilic asthma in adults: Current evidence and practical experience 198
Changed allergy pattern in outpatients 197
A WAO-ARIA-GA2LEN consensus document on molecular-based allergy diagnostics 197
Antiallergic drugs and quality of life. 194
Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. 193
Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria 193
CD40 on adult human airway epithelial cells: expression and proinflammatory effects 192
Allergic subjects express intercellular adhesion molecule-1 (ICAM-1 or CD54) on epithelial cells of conjunctiva allergen challenge. 191
T cell activation through different membrane structures (T3/Ti, T11, T44) and frequency analysis of proliferating and interleukin-2 producer T lymphocyte precursors in aged individuals. 190
A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). 189
Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma 189
The administration of a polyvalent mechanical bacterial lysate in elderly patients with COPD results in serological signs of an efficient immune response associated with a reduced number of acute episodes 188
Pharmacovigilance of drug allergy and hypersensitivity using the ENDA-DAHD database and the GALEN platform. The Galenda project. 187
A new protocol for specific oral tolerance induction in children with IgE-mediated cow's milk allergy. 187
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. 187
Sleep complaints and sleep breathing disorders in upper and lower obstructive lung diseases 186
30 Years Of Sublingual Immunotherapy 186
CD4+CD25highCD127- regulatory T-cells in COPD: Smoke and drugs effect 186
Inhibition of adhesion molecules by budesonide on a human epithelial cell line (lung carcinoma) 186
Functionally relevant decreases in activatory receptor expression on NK cells are associated with pulmonary tuberculosis in vivo and persist after successful treatment. 185
Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria-induced respiratory allergy: a randomized controlled trial. 184
Chronic Urticaria Patient Perspective (CUPP): The First Validated Tool for Assessing Quality of Life in Clinical Practice 184
COPD treatment: Real life and experimental effects on peripheral NK cells, their receptors expression and their IFN-γ secretion. 183
Allergic diseases and their impact on quality of life. 182
Eligibility for treatment with omalizumab in Italy and Germany 182
A role for the intranasal formulation of azelastine hydrochloride/fluticasone propionate in the treatment of allergic rhinitis 181
Basi Patogenetiche ed anatomopatologiche della flogosi allergica nell’asma bronchiale 180
Catching allergy by a simple questionnaire 179
The relationship between allergen immunotherapy and omalizumab for treating asthma 179
Comparison of the colony forming capacities of human T lymphocyte subpopulations. 178
Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - GAA) and World Allergy Organization (WAO) document endorsed by Allergic Rhinitis and its Impact on Asthma (ARIA) and Global Allergy and Asthma European Network (GA2LEN) 178
T cell activation surface markers and autologous mixed lymphocyte reaction do not differ in true and pseudo food allergy. 178
Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. 177
Allergic rhinitis and asthma ad hoc survey: clinical and psychological perspectives. 177
Sub-lingual administration of a polyvalent mechanical bacterial lysate (PMBL) in patients with moderate, severe, or very severe chronic obstructive pulmonary disease (COPD) according to the GOLD spirometric classification: A multicentre, double-blind, randomised, controlled, phase IV study (AIACE study: Advanced Immunological Approach in COPD Exacerbation) 176
Nasal immunotherapy to Parietaria: evidence of reduction of local allergic inflammation. 175
New insights into airway remodelling in asthma and its possible modulation. 175
Allergen-specific nasal challenge: response kinetics of clinical and inflammatory events to rechallenge. 175
The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy. 175
Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. 175
Clara cell 16 protein in COPD sputum: A marker of small airways damage? 175
Allergen-specific conjunctival challenge in children with allergic asthma: a clinical tool. 175
Antihistamines in atopic dermatitis. 174
Biomarkers and severe asthma: a critical appraisal. 174
Umeclidinium for the treatment of uncontrolled asthma 174
When to stop biologicals. Severe asthma exacerbation after mepolizumab discontinuation 174
100 years of immunotherapy: the Monaco charter. under the high patronage of His Serene Highness Prince Albert II of Monaco. 174
Inflammatory and mechanical factors of allergen-induced bronchoconstriction in mild asthma and rhinitis 173
Comparison of intranasal azelastine to intranasal fluticasone propionate for symptom control in moderate-to-severe seasonal allergic rhinitis 173
Viruses and bacteria in acute asthma exacerbations--a GA² LEN-DARE systematic review. 172
Biomarker discovery in asthma and COPD by proteomic approaches 172
Pidotimod: The state of art 172
Appropriateness in allergic respiratory diseases health care in Italy: Definitions and organizational aspects 172
Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma 172
The ARGA study with general practitioners: Impact of medical education on asthma/rhinitis management 172
Biosimilars in allergic diseases 172
Adherence to treatment: assessment of an unmet need in asthma. 171
Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA(2)LEN 170
Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. 170
Antiallergic activity of topical lodoxamide on in vivo and in vitro models. 170
Adherence to asthma treatments: 'We know, we intend, we advocate' 170
Allergenius, an expert system for the interpretation of allergen microarray results 170
Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. 169
Serum cytotoxic T lymphocyte-associated antigen 4 in hymenoptera venom allergy and its modulation by specific immunotherapy 169
Aerobiologic particle sampling by a new personal collector (Partrap FA52) in comparison to the Hirst (Burkard) sampler. 168
MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis 168
Focus on cat allergen (Fel d 1): immunological and aerodynamic characteristics, modality of airway sensitization and avoidance strategies. 168
The international survey on the management of allergic rhinitis by physicians and patients (ISMAR) 167
Recommendations for assessing patient-reported outcomes and health-related quality of life in patients with urticaria: a GA(2) LEN taskforce position paper. 167
Development and implementation of guidelines in allergic rhinitis – an ARIA-GA2LEN paper. 167
Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. 166
Standards for practical allergen-specific immunotherapy. 166
[Anti-leukotriene agents: rationale for and prospects of use]. 166
Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. 166
Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. 166
Totale 18.659
Salva come PNG Salva come JPEG
Categoria #
all - tutte 299.964
article - articoli 296.988
book - libri 0
conference - conferenze 310
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.666
Totale 599.928
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20227.039 0 0 0 1.298 189 694 666 1.804 336 710 278 1.064
2022/20237.156 791 301 38 688 1.146 1.568 13 565 1.426 62 466 92
2023/20242.797 193 537 62 272 242 453 132 129 151 52 146 428
2024/20258.865 121 857 358 555 1.341 948 784 1.158 340 508 722 1.173
2025/202616.244 1.663 444 1.011 1.255 1.867 2.150 3.005 665 1.048 1.367 843 926
2026/20276.853 1.965 516 1.680 2.692 0 0 0 0 0 0 0 0
Totale 97.067